Showing results (41-50 of 118) with videos related to

Sort By:
Pageof 12
Journal of the American Society of Nephrology : JASN|November 18, 2005
hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonistsYingjian Li, Xiaoyan Wen, Bradley C Spataro, et al.
Journal of the American Society of Nephrology : JASN|March 20, 2009
Wnt/beta-catenin signaling promotes renal interstitial fibrosisWeichun He, Chunsun Dai, Yingjian Li, et al.
The American Journal of Pathology|May 27, 2008
Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signalingMyrto Giannopoulou, Chunsun Dai, Xiaoyue Tan, et al.
Kidney Diseases (Basel, Switzerland)|May 16, 2024
Association of Serum Unsaturated Fatty Acid Patterns with the Risk of Diabetic NephropathyShuang Xu, Xinyuan Li, Qing Hou, et al.
Frontiers in Endocrinology|December 5, 2025
Urinary lipid metabolites and progression of kidney disease in individuals with type 2 diabetesYu Xiao, Caifeng Shi, Songyan Qin, et al.
Kidney International|May 28, 2010
Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuriaYoung Sun Kang, Yingjian Li, Chunsun Dai, et al.
Journal of Cellular and Molecular Medicine|December 2, 2017
FHL2 promotes tubular epithelial-to-mesenchymal transition through modulating β-catenin signallingTing Cai, Danqin Sun, Ying Duan, et al.
The American Journal of Pathology|January 19, 2008
Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuriaYingjian Li, Young Sun Kang, Chunsun Dai, et al.
Pageof 12